Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis
暂无分享,去创建一个
À. Rovira | X. Montalban | N. Téllez | M. Tintoré | J. Río | M. Comabella | L. Brieva | E. Julià | C. López
[1] C. Polman,et al. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis , 2005, Journal of Neurology.
[2] X. Montalban. Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis , 2004, Multiple sclerosis.
[3] W. Brück,et al. The role of cytokines and adhesion molecules in axon degeneration after peripheral nerve axotomy: a study in different knockout mice , 2003, Brain Research.
[4] Carlos Nos,et al. Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.
[5] M. Kaps,et al. Induction of sTNF‐R1 and sTNF‐R2 by interferon beta‐1b in correlation with clinical and MRI activity , 2001, Acta neurologica Scandinavica.
[6] P. Gallo,et al. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-b1a. , 2000 .
[7] Tarek A. Yousry,et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility , 1999, Neuroradiology.
[8] X. Montalban,et al. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. , 1999, Brain : a journal of neurology.
[9] Stephen M. Rao,et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.
[10] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[11] J. Dayer,et al. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. , 1997, European cytokine network.
[12] F. Barkhof,et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.
[13] F. Nicoletti,et al. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. , 1996, Cytokine.
[14] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[15] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[16] A. Broocks,et al. Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity , 1995, Annals of neurology.
[17] C A Smith,et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.
[18] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[19] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[20] D. Wallach,et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.
[21] C. Dinarello,et al. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. , 1991, The Journal of biological chemistry.
[22] D. Dripps,et al. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.
[23] C. Nathan,et al. Shedding of tumor necrosis factor receptors by activated human neutrophils , 1990, The Journal of experimental medicine.
[24] D. Wallach,et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.
[25] J. Dayer,et al. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. , 1989, The Journal of biological chemistry.
[26] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[27] M. Filippi,et al. Primary Progressive Multiple Sclerosis , 2002, Topics in Neuroscience.
[28] G. Wong,et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination , 1998, Nature Medicine.